BiotechTube

ATYR1940

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Facioscapulohumeral Muscular Dystrophy (FSHD)

Conditions

Facioscapulohumeral Muscular Dystrophy (FSHD)

Trial Timeline

Mar 30, 2016 → Dec 12, 2016

NCT ID
NCT02603562

About ATYR1940

ATYR1940 is a phase 1/2 stage product being developed by aTyr Pharma for Facioscapulohumeral Muscular Dystrophy (FSHD). The current trial status is completed. This product is registered under clinical trial identifier NCT02603562. Target conditions include Facioscapulohumeral Muscular Dystrophy (FSHD).

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (3)

NCT IDPhaseStatus
NCT02836418Phase 1/2Completed
NCT02603562Phase 1/2Completed
NCT02531217Phase 1/2Completed

Competing Products

12 competing products in Facioscapulohumeral Muscular Dystrophy (FSHD)

See all competitors
ProductCompanyStageHype Score
ACE-083 + ACE-083 or placeboMerckPhase 2
52
ACE-083MerckPhase 2
52
Placebo + RO7204239RochePhase 2
52
AOC-1020 + PlaceboAvidity BiosciencesPhase 3
74
Apitegromab + PlaceboScholar Rock HoldingPhase 2
49
Losmapimod oral tablet + Placebo oral tabletFulcrum TherapeuticsPhase 2
44
Losmapimod + Placebo oral tabletFulcrum TherapeuticsPhase 3
69
LosmapimodFulcrum TherapeuticsPhase 2
44
LosmapimodFulcrum TherapeuticsPhase 2
44
ATYR1940aTyr PharmaPhase 1/2
33
Placebo + ATYR1940aTyr PharmaPhase 1/2
33
ATYR1940aTyr PharmaPhase 1/2
33

Other Products from aTyr Pharma

Efzofitimod 1 mg/kg + Efzofitimod 3 mg/kg + PlaceboPhase 2
44
efzofitimod 450 mg + efzofitimod 270 mg + PlaceboPhase 2
44
ATYR1940Phase 1/2
33
Efzofitimod 1.0 mg/kg or Placebo + Efzofitimod 3.0 mg/kg or Placebo + Efzofitimod 5.0 mg/kg or PlaceboPhase 1/2
33
ATYR1940 + PlaceboPhase 1/2
33